- Home
- DLXY vs IMRN Comparison
DLXY vs IMRN Comparison
Compare DLXY & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLXY
- IMRN
- Stock Information
- Founded
- DLXY 2007
- IMRN 1994
- Country
- DLXY Singapore
- IMRN Australia
- Employees
- DLXY N/A
- IMRN N/A
- Industry
- DLXY
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- DLXY
- IMRN Health Care
- Exchange
- DLXY Nasdaq
- IMRN Nasdaq
- Market Cap
- DLXY 13.9M
- IMRN 14.4M
- IPO Year
- DLXY 2025
- IMRN N/A
- Fundamental
- Price
- DLXY $0.96
- IMRN $1.62
- Analyst Decision
- DLXY
- IMRN
- Analyst Count
- DLXY 0
- IMRN 0
- Target Price
- DLXY N/A
- IMRN N/A
- AVG Volume (30 Days)
- DLXY 61.4K
- IMRN 388.3K
- Earning Date
- DLXY 12-05-2025
- IMRN 08-29-2025
- Dividend Yield
- DLXY N/A
- IMRN N/A
- EPS Growth
- DLXY N/A
- IMRN N/A
- EPS
- DLXY 0.07
- IMRN N/A
- Revenue
- DLXY $314,916,000.00
- IMRN $4,777,422.00
- Revenue This Year
- DLXY N/A
- IMRN N/A
- Revenue Next Year
- DLXY N/A
- IMRN N/A
- P/E Ratio
- DLXY $15.03
- IMRN N/A
- Revenue Growth
- DLXY 8.90
- IMRN 48.63
- 52 Week Low
- DLXY $0.64
- IMRN $1.42
- 52 Week High
- DLXY $7.16
- IMRN $2.48
- Technical
- Relative Strength Index (RSI)
- DLXY N/A
- IMRN 43.49
- Support Level
- DLXY N/A
- IMRN $1.47
- Resistance Level
- DLXY N/A
- IMRN $1.69
- Average True Range (ATR)
- DLXY 0.00
- IMRN 0.11
- MACD
- DLXY 0.00
- IMRN 0.01
- Stochastic Oscillator
- DLXY 0.00
- IMRN 92.59
About DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.